Insulet Corporation (PODD) Stock Analysis
Falling Knife setup
Healthcare · Medical Devices
Hold if already holding. Not a fresh buy at $169.25, but acceptable to hold if already in. Reasons: Concentration risk — Product: Omnipod product platform; Concentration risk — Customer: Amgen.
Insulet Corporation develops and sells the Omnipod platform — a tubeless, wearable insulin delivery system — for people with insulin-dependent diabetes, with international sales comprising 28% of 2025 revenues. It also produces a customized Pod for Amgen's Neulasta Onpro drug... Read more
Hold if already holding. Not a fresh buy at $169.25, but acceptable to hold if already in. Reasons: Concentration risk — Product: Omnipod product platform; Concentration risk — Customer: Amgen. Chart setup: Death cross, below all MAs, RSI 29, MACD bearish. Maintain position. Not compelling to add more. Score 5.6/10, moderate confidence.
Passes 4/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, semi cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA) and news soft fda negative and earnings proximity 6d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductOmnipod product platform10-K Item 1A: 'We expect to continue to derive nearly all our revenue from our Omnipod product platform.'
- HIGHCustomerAmgen10-K Item 1A: 'Substantially all of our commercialized Drug Delivery revenue consists of sales of a customized version of our product for use in Amgen's Neulasta Onpro kit under an agreement that expires in December 2028.'
Material Events(8-K, last 90d)
- 2026-02-24Item 4.01HIGHAuditor change: Grant Thornton LLP dismissed after completing fiscal 2025 audit. PricewaterhouseCoopers LLP selected as independent auditor for fiscal year ending December 31, 2026. No disagreement cited.SEC filing →
- 2026-03-04Item 5.02LOWAna M. Chadwick (former CFO) entered severance agreement on February 27, 2026. No material compensation differences from previously disclosed terms; includes standard release and non-disparagement provisions.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $169.25, but acceptable to hold if already in. Reasons: Concentration risk — Product: Omnipod product platform; Concentration risk — Customer: Amgen. Chart setup: Death cross, below all MAs, RSI 29, MACD bearish. Maintain position. Not compelling to add more. Target $293.71 (+73.5%), stop $157.56 (−7.4%), A.R:R 8.4:1. Score 5.6/10, moderate confidence.
Take-profit target: $293.71 (+73.4% upside). Target $293.71 (+73.5%), stop $157.56 (−7.4%), A.R:R 8.4:1. Stop-loss: $157.56.
Concentration risk — Product: Omnipod product platform; Concentration risk — Customer: Amgen; Earnings in 6 days (event risk).
Insulet Corporation trades at a P/E of 46.1 (forward 19.8). TrendMatrix value score: 5.8/10. Verdict: Hold.
34 analysts cover PODD with a consensus score of 4.3/5. Average price target: $326.
What does Insulet Corporation do?Insulet Corporation develops and sells the Omnipod platform — a tubeless, wearable insulin delivery system — for people...
Insulet Corporation develops and sells the Omnipod platform — a tubeless, wearable insulin delivery system — for people with insulin-dependent diabetes, with international sales comprising 28% of 2025 revenues. It also produces a customized Pod for Amgen's Neulasta Onpro drug delivery kit, which constitutes substantially all Drug Delivery segment revenue.